Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.37 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13424803 | 0.86 | PARP1 (0.47) | NR3C2ADRB2IL4I1PARP1ADRB1 | |
| SCHEMBL8201338 | 0.85 | NR3C2 (0.37) | NR3C2ADRB2IL4I1PARP1ALDH1A1 | |
| SCHEMBL13181783 | 0.81 | PARP1 (0.37) | NR3C2ADRB2IL4I1PARP1ALDH1A1 | |
| SCHEMBL14080051 | 0.81 | IL4I1 (0.39) | NR3C2ADRB2IL4I1PARP1MAPT | |
| SCHEMBL13424831 | 0.76 | MMP12 (0.45) | NR3C2PARP1MAPTPDE3BPDE3A | |
| SCHEMBL8191716 | 0.76 | PDE3B (0.41) | NR3C2ADRB2IL4I1PARP1ALDH1A1 | |
| SCHEMBL5217579 | 0.76 | GAA (0.44) | NR3C2ADRB2ALDH1A1MAPTPDE3B | |
| SCHEMBL5343358 | 0.76 | HTR1A (0.44) | NR3C2ADRB2IL4I1PARP1ADRB1 | |
| SCHEMBL5251708 | 0.76 | NR3C2 (0.51) | NR3C2PARP1ALDH1A1MAPTADRB1 | |
| SCHEMBL8197296 | 0.74 | BRD4 (0.39) | NR3C2ADRB2PARP1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | NR3C2 5/4885ADRB2 82/4885IL4I1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.